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The entry of retroviruses into their target cell involves interactions between the virus envelope glycoproteins and their
cellular receptors, as well as accessory ligand–receptor interactions involving adhesion molecules that can also participate
in fusion. We have studied the contribution of CD82 proteins to the transmission of the human T-cell leukemia virus type 1
(HTLV-1), which is greatly dependent on cell-to-cell contacts. CD82 proteins belong to a class of cell surface molecules, the
tetraspanins, that can act as molecular facilitators in cellular adhesion processes. The coexpression of CD82 proteins with
HTLV-1 envelope glycoproteins resulted in marked inhibition of syncytium formation, whereas CD82 proteins had no effect
on syncytium formation induced by human immunodeficiency virus type 1 (HIV-1) envelope proteins. The presence of CD82
proteins also inhibited cell-to-cell transmission of HTLV-1. Coimmunoprecipitation and cocapping experiments showed that
CD82 associates with HTLV-1 envelope glycoproteins, both within the cell and at the cell surface. Finally, whereas the
intracellular maturation of HTLV-1 glycoproteins was not modified by the presence of CD82 proteins, HTLV-1 protein
coproduction delayed the intracellular maturation of CD82 proteins. There thus seems to be a reciprocal interaction between
virus and cell proteins, and the cellular proteins involved in adhesion modulate retrovirus transmission both positively, as
shown in other systems, and negatively, as shown here. © 2000 Academic PressINTRODUCTION
Type C retroviruses are enveloped viruses, which ac-
quire their envelope during budding of the virus particle
through the plasma membranes of infected cells. This
envelope contains virus-encoded heterodimeric glyco-
proteins, composed of an external glycoprotein, the sur-
face protein (SU), and a membrane-spanning glycopro-
tein, the transmembrane (TM) protein, which anchors the
SU-TM heterodimer at the surface of the infected cell or
the virion. The entry of retroviruses into their target cells
involves an interaction between the SU part of the enve-
lope glycoproteins and cell receptors, followed by con-
formational changes, allowing the TM subunit of the
virus glycoproteins to mediate fusion of the cellular and
viral membranes (reviewed in Hunter and Swanstrom,
1990; Schulz et al., 1992; Chan and Kim, 1998).
Other ligand–receptor interactions involving cell-de-
rived surface molecules can also help initiate fusion in
the human immunodeficiency virus type 1 (HIV-1), in
addition to the essential interactions between the virus
glycoproteins and their cellular receptors (Hildreth and
1 These authors contributed equally to this work.
2 To whom correspondence and reprint requests should be ad-dressed at Hoˆpital St Louis, CNRS UPR 9051, 1 av. Claude Vellefaux,
Paris 75010, France. Fax: 33 1 53 72 40 90. E-mail: pique@chu-stlouis.fr.
455Orentas, 1989; Valentin et al., 1990; Gruber et al., 1991).
HIV-1 incorporates several host cell components into
nascent particles during the budding out of infected cells
(Arthur et al., 1992; Meerloo et al., 1993; reviewed in
Tremblay et al., 1998), with the profile of molecules in the
virion envelope, depending on the producing cell type
(Bastiani et al., 1997). In particular, MHC class II mole-
cules or proteins that regulate cell-to-cell adhesion, such
as the intercellular adhesion molecule 1 (ICAM-1), can
facilitate fusion and infectivity and be incorporated into
HIV-1 virions (Berman and Nakamura, 1994; Butini et al.,
1994; Cantin et al., 1998; Fortin et al., 1997; Rizzuto and
Sodroski, 1998; Tsunetsugu-Yokota et al., 1997).
There is less evidence as to whether host proteins
also modulate the biological properties of retroviruses
not belonging to the lentivirus genus. Human T-cell leu-
kemia virus type 1 (HTLV-1), a type C retrovirus and the
cause of adult T-cell leukemia and tropical spastic para-
paresis, is found primarily in T cells in vivo, but can infect
a variety of cell types in vitro. Transmission of HTLV-1
depends greatly on cell-to-cell contacts, and free HTLV-1
particles are very poor infectious agents (Yamamoto et
al., 1982; Popovic et al., 1983; Okochi et al., 1984; Manns
et al., 1992; Kleinman et al., 1993; Donegan et al., 1994),
although particles seem to form normally and bud from
infected cells. Like that of the other retroviruses, HTLV-1
transmission requires interaction between the virus gly-
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456 PIQUE ET AL.coproteins and a cellular receptor that has not yet been
identified. HTLV-1 virus particles can also incorporate
host cell-derived proteins, such as those that control the
complement immune effector mechanism (Spear et al.,
995), and the ICAM-1, ICAM-3, and V-CAM adhesion
olecules serve as accessory molecules in HTLV-1-
nduced fusion (Hildreth et al., 1997; Daenke et al., 1999).
his suggests that members of the integrin superfamily
f adhesion molecules positively regulate the infectivity
f HTLV-1 as they do for HIV-1.
Other cell surface proteins, including the CD82 tet-
aspanins, have been implicated in HTLV-1-induced cell
usion (Fukudome et al., 1992b). Tetraspanin cell surface
roteins have similar sequences and structures, with
our membrane-spanning domains delimiting two extra-
ellular regions of unequal size; they also have similar
iochemical and functional properties (reviewed in
aecker et al., 1997). They are present in a wide variety
f cells and tissues. The CD82 protein concentration on
lymphocytes is increased upon activation and HTLV-1
nfection (Shibagaki et al., 1998; Imai et al., 1992). CD82
roteins form multimeric complexes with various surface
roteins, including the CD4 and CD8 proteins (Imai and
oshie, 1993b), major histocompatibility complex mole-
ules (Angelisova et al., 1994; Lagaudrie`re-Gesbert et al.,
997; Hammond et al., 1998), other tetraspanins, and b1
ntegrins (Rubinstein et al., 1996; Mannion et al., 1996).
he ability of CD82 proteins to interact with many other
ignaling and adhesion molecules and act as “molecular
acilitators” (Maecker et al., 1997) prompted us to exam-
ne their capacity to modulate HTLV-1 envelope-medi-
T
Overproduction of CD82 Inhibits HTLV-1, but
Transfected plasmidb Plasmid ratioc
CMV-ENV 1 CMV-Ex-pA2 1:1
CMV-ENV 1 CD82 1:1
CMV-ENV 1 CMV-Ex-pA2 1:10
CMV-ENV 1 CD82 1:10
PMA-243 1 CMV-Ex-pA2 1:1
PMA-243 1 CMV-CD82 1:1
PMA-243 1 CMV-Ex-pA2 1:200
PMA-243 1 CMV-CD82 1:200
PMA-243 1 T4rec 1:200
a Syncytium formation was quantified using a cell-fusion assay based
ata are from one representative experiment out of three performed.
b CMV-ENV is a eucaryotic expression vector of the HTLV-1 envelop
is a eucaryotic expression vector of the CD82 proteins; PMA-243 is a
is a eucaryotic expression vector of the CD4 proteins.
c For the 1:1 ratio, 1 mg of each plasmid was used; for the 1:10 ratio
and 2 mg of the plasmids were used.
d Results are expressed as chemoluminescent units after subtractioted functions. Surprisingly, the presence of CD82 pro-
eins on cells reduced the ability of HTLV-1 envelopelycoproteins to induce the formation of syncytia,
hereas it had no effect on HIV-1 envelope-mediated
usion. HTLV-1 cell-to-cell transmission was also inhib-
ted by the presence of CD82 proteins on virus-producing
ells, although the incorporation of envelope proteins
nto HTLV-1 particles was not affected. This was corre-
ated with the association between HTLV-1 and CD82
lycoproteins at the cell surface. Thus, the cell proteins
nvolved in adhesion modulate retrovirus transmission
ot only positively, but also negatively.
RESULTS
nhibition of HTLV-1, but not HIV-1, envelope-mediated
yncytium formation by CD82 in cotransfection
xperiments
We tested the effect of CD82 proteins on HTLV-1 en-
elope-mediated functions by assessing the effect of
D82 proteins plus HTLV-1 glycoprotein synthesis on
yncytium formation. COS-1 cells overproducing both
D82 and the HTLV-1 envelope glycoproteins had less
usion capacity than did COS-1 cells producing only the
TLV-1 glycoproteins (Table 1). The effect of CD82 co-
xpression on HTLV-1-induced syncytium formation was
nhanced by increasing the concentration of the CD82-
ncoding plasmid in cotransfection experiments. Adding
he anti-CD82 MAb, gC11, at the beginning of the culture
period did not reverse the inhibition by CD82 proteins
(data not shown).
The specificity of the inhibition in the presence of
CD82 proteins was assessed in similar experiments per-
-1, Envelope-Mediated Syncytium Formation
Syncytium formationa
Galactosidase productiond Percentage inhibition
804,840 —
340,933 58
307,029 —
67,787 78
10,813,839 —
9,076,167 16
2,029,997 —
2,130,582 0
309,273 85
galactosidase production, as described under Materials and Methods.
proteins; CMV-Ex-pA2 is the corresponding empty vector; CMV-CD82
otic expression vector of the HIV-1 envelope glycoproteins; and T4rec
g and 2 mg of the plasmids were used; and for the 1:200 ratio, 10 ng
e background.ABLE 1
Not HIV
b-
on b-
e glyco
eucaryformed with HIV-1 envelope glycoproteins. The produc-
tion of CD82 proteins did not affect syncytium formation
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457CD82 INHIBITS HTLV-1 ENVELOPE GLYCOPROTEIN FUNCTIONSinduced by the HIV-1 envelope glycoproteins, even when
a 200-fold excess of CD82 expressor plasmid was used
(Table 1). There was 85% inhibition of the HIV-1-induced
cell-to-cell fusion at this ratio when a CD4 expressor was
cotransfected with the HIV-1 envelope expressor plas-
mid, indicating the validity of the assay.
Thus, overproduction of CD82 tetraspanins in cells
producing HTLV-1 envelope glycoproteins reduced their
fusion capacity, but not that of HIV-1 envelope glycopro-
teins.
Inhibition of HTLV-1 cell-to-cell transmission by CD82
in cotransfection experiments
We next investigated whether CD82 could also affect
HTLV-1 infectivity. HTLV-1 is transmitted mainly via cell-
to-cell contacts, both in vivo (Okochi et al., 1984; Manns
t al., 1992; Kleinman et al., 1993; Donegan et al., 1994)
nd in vitro (Miyamoto et al., 1984; Popovic et al., 1983).
herefore, we examined the effect of CD82 proteins on
TLV-1 transmission, using an infectivity assay (Del-
marre et al., 1997) in which the HTLV-1 transmission
ccurring in one round of infection was measured by the
umber of neomycin-resistant clones produced. Fewer
lones were produced when the CD82 proteins were
ynthesized along with HTLV-1 (Table 2). Infectivity was
ompletely blocked by transfection with a 10-fold excess
f CD82 expressor over envelope plasmid.
Hence, overproduction of CD82 proteins also reduced
he infectivity of HTLV-1.
ormal production and incorporation into HTLV-1
articles of SU and TM envelope proteins in the
resence of CD82 proteins
TABLE 2
Overproduction of CD82 Inhibits HTLV-1 Cell-To-Cell Transmission
Transfected plasmid
Infectivitya
Plasmid
ratiob
Number of
clonesc
Percentage
inhibition
CMV-ENV 1 CMV-Ex-pA2 1:1 83 —
CMV-ENV 1 CMV-CD82 1:1 36 57
CMV-ENV 1 CMV-Ex-pA2 1:10 82 —
CMV-ENV 1 CMV-CD82 1:10 4 95
a COS-1 cells were transfected with the pCS-HTLV-1-neo plasmid
nd with the indicated plasmids; the HTLV-1 infectivity was evaluated
y counting neomycin-resistant clones. Data are from one representa-
ive experiment out of three performed.
b Ratios of CD82 and envelope expressors were the same as in
Table 1.
c No clone was observed in mitomycin-treated COS-1 cells not cul-
ivated with B5 cells.HTLV-1 envelope proteins, like all retroviral glycopro-
eins, are synthesized as a single precursor that entershe endoplasmic reticulum (ER), is transported to the
olgi, and is cleaved to give two mature subunits, SU
nd TM (Hunter and Swanstrom, 1990). The transport of
he mature SU and TM proteins to the cell surface is
equired for envelope-mediated syncytium formation and
or the incorporation of envelope proteins into budding
TLV-1 particles.
The effect of CD82 overproduction on SU and TM
roduction was first examined. Similar amounts of both
U and TM proteins could be immunoprecipitated from
nvelope protein-expressing cells, whether they also
roduced CD82 proteins (Fig. 1, lane 3) or not (Fig. 1, lane
). The presence or absence of CD82 did not influence
he apparent molecular weight of the precursor or the SU
nd TM envelope proteins, which showed that the N-
lycosylation process of the HTLV-1 glycoproteins was
ot disturbed by CD82. These results indicate that the
egative effect of CD82 proteins on syncytium formation
nd cell-to-cell transmission is not the result of quanti-
ative or qualitative defects in the production of SU and
M glycoproteins in cotransfected cells.
We then examined whether the loss of infectivity that
ccurred in the presence of CD82 proteins was caused
y inefficient HTLV-1 virus production or glycoprotein
ncorporation into virions. Retrovirus particles were pro-
uced by cotransfecting cells with an expressor of Gag
roteins (pCS-HTLV-neo) and the envelope expression
lasmid. They were purified on sucrose gradients, and
irus proteins were then immunoprecipitated. The pro-
uction of both CD82 proteins and the virus proteins led
o a slight increase in particle release into the superna-
ants (visualized by increased Gag protein detection) and
parallel increase in SU glycoproteins in virions (Fig. 2;
ompare lanes 3 and 4). A control was performed to
nsure that envelope glycoproteins detected were not
FIG. 1. Influence of CD82 proteins on the intracellular maturation of
HTLV-1 envelope glycoproteins. HTLV-1 envelope proteins were immu-
noprecipitated from COS-1 cells transfected with the CMV-ENV HTLV-1
envelope expressor plasmid or the CMV-ENV-DPvuII negative control
plasmid, which contains a nonsense codon at the beginning of the ENV
gene, and with or without the CMV-CD82 expressor. Lane 1: CMV-ENV-
DPvuII; lane 2: CMV-ENV and mock plasmid DNA; lane 3: CMV-ENV
and CMV-CD82.
458 PIQUE ET AL.from cell membranes, vesicles, or blebs purified with
virus particles, as these are frequent contaminants of
virion preparations. Comparison of the amounts of enve-
lope proteins detected in the absence of Gag proteins
(representing contaminations; Fig. 2, lane 2) and those in
the presence of Gag proteins (Fig. 2, lane 4) showed that
envelope glycoproteins detected when CD82 proteins
were present corresponded to true incorporation.
Thus, the presence of CD82 proteins did not prevent
virion release or envelope incorporation onto virions.
Moreover, since envelope proteins are incorporated at
the plasma membrane, these results show indirectly that
the transport of envelope glycoproteins to the cell sur-
face was not affected by CD82 proteins.
Association of CD82 proteins with HTLV-1, but not
HIV-1, envelope glycoproteins
Like other tetraspanins, CD82 can associate with a
wide range of cell surface proteins (reviewed in Maecker
et al., 1997). We therefore looked for an interaction be-
tween CD82 proteins and HTLV-1 envelope glycopro-
teins. The CD82 proteins are synthesized as immature
35-kDa products in the ER and are further N-glycosylated
to give mature forms of higher molecular weight in the
Golgi apparatus. These forms are from 40 to 55 kDa on
resting T cells to up to 70 kDa on activated or HTLV-1-
infected T cells (Fukudome et al., 1992b; Imai et al., 1992).
Immunoprecipitation of the HTLV-1 envelope glycopro-
teins with the 4D4 anti-envelope MAb (Fig. 3A, lane 5) or
serum from HTLV-1-infected individuals (Fig. 3A, lane 6)
precipitated the immature (35 kDa) and mature forms
(40–55 kDa) of the CD82 proteins from cells producing
FIG. 2. Influence of CD82 proteins on the incorporation of HTLV-1
envelope proteins into virions. HTLV-1 envelope proteins in virions
purified from supernatants of transfected COS-1 cells. Virions were
produced by cotransfection of COS-1 cells with the pCS-HTLV-1-neo
provirus and the CMV-ENV HTLV-1 envelope expressor plasmid and
with or without the CMV-CD82 expressor. Lane 1: CMV-ENV and mock
DNA; lane 2: CMV-ENV and CMV-CD82; lane 3: pCS-HTLV-1-neo plus
CMV-ENV and mock plasmid DNA; lane 4: pCS-HTLV-1-neo plus CMV-
ENV and CMV-CD82. The positions of the p24 and p19 HTLV-1 gag
proteins and of the SU envelope proteins are indicated.both envelope and CD82 proteins. Only background
bands were observed either in cells overproducing CD82(Fig. 3A, lanes 1 and 2) or HTLV-1 glycoproteins alone
(Fig. 3A, lanes 3 and 4). Furthermore, CD82 proteins were
not detected in immunoprecipitates containing HIV-1 en-
velope glycoproteins (Fig. 3C, lane 4), although CD82
proteins were found in immunoprecipitates containing
HTLV-1 glycoproteins under these conditions (Fig. 3C,
lane 2). These experiments demonstrate that both pre-
cursor and highly glycosylated forms of CD82 proteins
associate with the HTLV-1 envelope, whereas they did
not interact with the HIV-1 glycoproteins. This associa-
tion of HTLV-1 envelope proteins with CD82 proteins
occurs in the ER and the two proteins remain associated
during their transit through the secretory pathway. Elim-
ination of HTLV-1 envelope proteins from cell lysates
using antibodies resulted in decreased amounts of CD82
proteins recovered from cotransfected cells (data not
shown). This indicates that most of the CD82 proteins
are associated with the HTLV-1 glycoproteins within co-
transfected cells.
FIG. 3. Association of CD82 proteins with the HTLV-1 glycoproteins
but not with the HIV-1 envelope proteins. CD82 proteins in immuno-
precipitates containing the HTLV-1 (A, B) or the HIV-1 envelope proteins
(C) were detected in immunoblots revealed with the gC11 MAb. (A)
Presence of CD82 proteins in HTLV-1 envelope protein immunoprecipi-
tates from transfected COS-1 cells. Lanes 1 and 2: CMV-CD82 expres-
sor; lanes 3 and 4: CMV-ENV HTLV-1 envelope expressor; lanes 5 and
6: CMV-CD82 and CMV-ENV expressors. HTLV-1 envelope proteins
were immunoprecipitated with the 4D4 anti-envelope MAb (lanes 1, 3,
and 5) or with sera from HTLV-1-infected individuals (lanes 2, 4, and 6).
(B) Presence of CD82 proteins in HTLV-1 envelope protein immunopre-
cipitates, from T-cell lines chronically infected by HTLV-1, or not. Lanes
1 and 2: C91/PL-infected cells; lanes 3 and 4: uninfected Jurkat cells.
Proteins were immunoprecipitated with 4D4 anti-envelope MAb (lanes
1 and 3) or the anti-HTLV-1 human sera (lanes 2 and 4). (C) Presence
of CD82 proteins in HIV-1 (or HTLV-1) envelope protein immunoprecipi-
tates, from transfected COS-1 cells. Lanes 1 and 2: CMV-ENV HTLV-1
envelope glycoprotein expressor; lanes 3 and 4: pMA-243 HIV-1 enve-
lope expressor in the presence of the CD82 plasmid (lanes 2 and 4) or
not (lanes 1 and 3). HTLV-1 and HIV-1 envelope glycoproteins were
immunoprecipitated using sera from infected individuals. Lanes C: cell
lysates from COS-1 cells transfected with the CMV-CD82 plasmid, used
as positive control for the Western blot.
459CD82 INHIBITS HTLV-1 ENVELOPE GLYCOPROTEIN FUNCTIONSAssociation between CD82 proteins and HTLV-1
glycoproteins in T cells chronically infected with
HTLV-1
We determined whether the association between CD82
proteins and HTLV-1 envelope glycoproteins also occurs in
cells chronically infected with HTLV-1. Anti-envelope glyco-
protein antibodies were used to immunoprecipitate the viral
products of infected C91/PL T cells, and the presence of
CD82 proteins in the immunoprecipitates was subse-
quently examined as performed earlier.
Again, CD82 proteins were detected in C91/PL cell ly-
sates immunoprecipitated with either of the anti-envelope
antibodies used (Fig. 3B, lanes 1 and 2), but not in unin-
fected control Jurkat T cells (Fig. 3B, lanes 3 and 4). The
apparent molecular weight of the associated CD82 proteins
recovered from C91/PL was higher than those detected in
cotransfected cells (compare Figs. 3A and 3B). This was
expected, since highly N-glycosylated forms of CD82 are
produced in HTLV-1-infected T-cell lines (Fukudome et al.,
1992). However, immature forms of CD82 were also de-
tected in immunoprecipitates from C91/PL, which showed
that envelope and CD82 proteins also associate early in the
secretory pathway in HTLV-1-infected T-cell lines.
HTLV-1 envelope glycoproteins also associate with
CD82 proteins at the surface of chronically
infected T cells
The association between the two molecules at the cell
surface was investigated in cocapping experiments on
MT2 cell lines chronically infected with HTLV-1 (Fig. 4).
Both molecules were labeled and the capping of one of
them was induced by crosslinking with a species-spe-
cific secondary MAb followed by a short incubation at
37°C (30 min to reduce endocytosis). Confocal micros-
copy showed that CD82 and envelope proteins were
both in large caps (Figs. 4C and 4F), whether HTLV-1
glycoproteins (Figs. 4A–4C) or CD82 (Figs. 4D–4F) had
been induced to cap. Similar results were obtained with
the other cell line chronically infected by HTLV-1 C91/PL
(data not shown). In contrast, the ICAM-1 molecule re-
mained uniformly distributed around the cells upon cap-
ping of the HTLV-1 envelope glycoproteins (Figs. 4J and
4K) and there was no colocalization with the HTLV-1
glycoproteins (Fig. 4L). The HIV-1 envelope glycoproteins
(Fig. 4G) and CD82 (Fig. 4H) were not colocalized (Fig. 4I)
when cocapping with the corresponding antibodies was
performed on HIV-1 chronically infected CEM-NDK cells.
These results demonstrated that HTLV-1 envelope glyco-
proteins specifically associate with CD82 proteins not
only within the cells but also at the surface of HTLV-1-
infected T cells.
Delayed CD82 maturation in cotransfected cellsWe further confirmed the physical association be-
tween the viral and cellular proteins by determiningwhether this association altered the intracellular matu-
ration of CD82 proteins. Preliminary experiments
showed a slight increase in the amount of the 35-kDa
immature product in cotransfected cells (data not
shown). This observation was confirmed by measuring
the rate of CD82 maturation in COS-1 cells, in the pres-
ence (or not) of HTLV-1, or of HIV-1 envelope glycopro-
teins as control. When the CD82 proteins were produced
alone, the mature 40- to 55-kDa forms of CD82 appeared
after 0.5 h of chase and the immature 35-kDa form was
no longer detected after 2 h (Fig. 5; times 0, 0.5, and 2,
lanes 1). The rate of CD82 maturation was almost the
same in the presence of the HIV-1 glycoproteins, al-
though small amounts of the immature CD82 forms were
still detected even after a 6-h chase period (Fig. 5, lanes
3). In contrast, the appearance of the highly glycosylated
forms was markedly delayed in the presence of HTLV-1
glycoproteins, and large amounts of immature CD82
were still detected after the 2- and 6-h chase periods
(Fig. 5, lanes 2). Thus, our results show reciprocal inter-
actions between CD82 and HTLV-1 glycoproteins, dem-
onstrating that, whereas CD82 proteins affect the HTLV-1
FIG. 4. Colocalization of HTLV-1 or HIV-1 envelope proteins with
cellular proteins at the surface of HTLV-1 (MT2) or HIV-1 (CEM-NDK)
chronically infected cells. HTLV-1 (A–C, J–L) or HIV-1 (G–I) envelope
glycoproteins were capped with FITC-labeled anti-human MAbs; CD82
(A–C, G–I) or ICAM-1 (J–L) were capped with cyanin-3-labeled anti-
mouse MAbs. In D–F, capping of CD82 with anti-mouse MAbs was first
induced to cap, and HTLV-1 glycoproteins were revealed with FITC-
labeled anti-human MAbs. A, D, J: FITC staining of HTLV-1 glycoprotein;
B, E, H: cyanin-3 staining of CD82; G: FITC staining of HIV glycopro-
teins, K: cyanin-3 staining of ICAM-1; C, F, I, L: superposition of FITC
and cyanin-3 stainings.envelope-mediated functions, HTLV-1 glycoproteins de-
lay the intracellular maturation of CD82 proteins.
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460 PIQUE ET AL.DISCUSSION
We have investigated whether CD82 tetraspanin pro-
eins, which are involved in cell adhesion (Mannion et al.,
996; Shibagaki et al., 1998) and associate with various
ransmembrane receptors (Imai and Yoshie, 1993b; Imai
t al., 1995; Lagaudrie`re-Gesbert et al., 1997), modulate
TLV-1 envelope-mediated functions. We used cotrans-
ection experiments in COS-1 cells to show that HTLV-1-
nduced syncytium formation and cell-to-cell transmis-
ion were reduced by CD82 proteins, whereas HIV-1
nvelope-mediated functions remained unaffected under
he same conditions. We also demonstrated that CD82
nd HTLV-1 envelope proteins are associated, both
ithin the cell and at the cell surface. Hence our results
rovide the first demonstration that a direct association
f tetraspanins with retrovirus envelope proteins affects
nvelope-mediated functions.
The inhibition of syncytium formation and infectivity
annot be the result of a defect in the intracellular mat-
ration of HTLV-1 glycoproteins caused by CD82 pro-
eins, because the amounts and apparent molecular
eights of the envelope glycoprotein precursor, and
hose of mature SU and TM glycoproteins, were not
nfluenced by the presence of CD82 proteins. The incor-
oration of envelope glycoproteins into virion particles
lso remained unchanged. By contrast, two complemen-
ary techniques, coimmunoprecipitation and cocapping,
emonstrated the association of envelope and CD82
roteins. This association began early along the biosyn-
hesis pathway, as shown by disturbed synthesis of
D82 ER products, and was maintained at the cell sur-
ace. The finding that another retrovirus glycoprotein,
hat of HIV-1, which uses maturation pathways similar to
hose of HTLV-1 glycoproteins, had no effect on CD82
ntracellular maturation points to a specific interaction
etween CD82 and HTLV-1 proteins.
FIG. 5. HTLV-1 envelope glycoproteins delay the intracellular matu-
ration of CD82 in cotransfected COS-1 cells. Lane 1: CMV-CD82 ex-
pressor plasmid and mock plasmid DNA; lane 2: CMV-CD82 and
CMV-ENV HTLV-1 envelope expressor plasmids; lane 3: CMV-CD82
and pMA-243 HIV-1 envelope expressor plasmids. Transfected COS-1
cells were pulse-labeled and lysed (time 0) or chased for 0.5, 2, or 6 h.
The positions of the immature and mature forms of CD82 proteins are
indicated.Tetraspanin proteins other than CD82 are important
egulators of virus infection. The CD9 tetraspanin protein
a
1odulates infection by feline immunodeficiency virus
FIV), and renders cells permissive to infection by canine
istemper virus (CDV), a lymphotropic and neurotropic
orbillivirus. Human CD81 tetraspanin has been identi-
ied as a putative receptor for the hepatitis C virus (HCV)
lycoprotein. Whether these tetraspanin proteins are the
ey receptor molecules for attachment of the virus to
ells, however, is not yet known. No direct binding of
DV to CD9 could be detected, and anti-CD9 MAbs may
nhibit virus release rather than interfere with receptors
de Parseval et al., 1997). Also, the binding of HCV E2
lycoprotein to CD81 is not correlated with permissive-
ess to HCV infection (Meola et al., 2000). Perhaps CD82
roteins act as receptor molecules in HTLV-1 infection;
hey certainly satisfy two criteria usually assigned to
irus receptors. They associate with envelope glycopro-
eins early in the cell, as CD4 and HIV-1 glycoproteins do,
nd their overproduction causes reduced of fusion, as
lso observed with CD4 and HIV-1. However, contrary to
he case with overproduction of CD4 and HIV-1 (Willey et
l., 1992; Ross et al., 1999), CD82 does not modulate the
aturation of HTLV-1 envelope glycoproteins or the re-
ease of virions.
Neither could we modify the susceptibility to HTLV-1
nfection after stable transfection of low-producing cells
ith CD82 cDNA. Furthermore, we detected no inhibition
f fusion by anti-CD82 antibodies using a panel of cell
ines as targets (data not shown). This indicates that
D82 proteins are probably not receptors of HTLV-1, but
ather affect the capacity of HTLV-1 envelope glycopro-
ein to mediated cell-to-cell fusion and transmission by a
irect steric hindrance of envelope–receptor interac-
ions. The results obtained by others with anti-CD82
ntibodies (Fukudome et al., 1992b) are probably ex-
lained by such hindrance. Overproduced CD82 proteins
ither mask the domain of HTLV-1 glycoproteins involved
n the interaction with their cellular receptor or disturb
he envelope conformational changes required for fu-
ion.
This type of hypothesis requires estimation of the
espective amounts of envelope and CD82 proteins
resent during virus production, and whether these are
imilar in our experiments to those in HTLV-1-infected T
ymphocytes in vivo. We found that the amounts of CD82
roteins in four HTLV-1 chronically infected T-cell lines
ere one- to twofold those of HTLV-1 glycoproteins (data
ot shown). These chronically infected T cells produce
ery large amounts of viral proteins, and might not be
ood indicators of the HTLV-1 production of circulating T
ymphocytes in vivo. Peripheral blood lymphocytes of
TLV-1-infected individuals has recently been shown to
roduce HTLV-1 Tax and GAG proteins (Hanon et al.,
000). It is very likely that envelope proteins are also
roduced, as indicated by the presence of anti-envelope
ntibodies in the sera of infected individuals (Chen et al.,
989). HTLV-1-infected cells could synthesize amounts of
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461CD82 INHIBITS HTLV-1 ENVELOPE GLYCOPROTEIN FUNCTIONSCD82 and HTLV-1 glycoproteins similar to those found in
HTLV-1 chronically infected cells. In addition, the physi-
ological situations that lead to augmented CD82 protein
synthesis, such as T-cell activation (Shibagaki et al.,
1998; Lebel-Binay et al., 1995), will probably change the
CD82/HTLV-1 glycoprotein ratio, thus modulating the ca-
pacity of infected T lymphocytes to transmit the virus.
These mechanisms that reduce retroviral envelope-
mediated fusion and, generally also, infectivity appear to
be most important in the biology of retroviruses. Selec-
tion seems to have occurred to maintain a balanced
fusion capacity of retroviral envelopes rather than a max-
imal one. In HTLV-1, as in simian immunodeficiency virus
(SIV) and HIV-1, some artificially mutated envelope gly-
coproteins have a much greater fusion capacity than the
wild-type proteins (Pique et al., 1993; Ritter et al., 1993;
Zingler and Littman, 1993; Gabuzda et al., 1992; Mulligan
et al., 1992), which shows that circulating virus strains
have retained a submaximal fusion capacity. Mutated SIV
glycoproteins that produce greater fusion in vitro are
rapidly counterselected in vivo (Kodama et al., 1989).
Glycoproteins with intermediate fusion capacities might
avoid massive fusion between infected and target cells,
which would lead to elimination of the virus. The asso-
ciation of CD82 molecules with HTLV-1 envelope glyco-
proteins should perhaps be considered in this context,
as it could lead to the fine-tuning of HTLV-1 fusion ca-
pacity.
Whereas CD82 proteins modulate HTLV-1 functions,
HTLV-1 glycoproteins delay the intracellular maturation
of CD82 proteins, emphasizing that virus and cell have
reciprocal influences. An earlier study found that the
maturation of CD82 proteins was abnormal in HTLV-1
chronically infected cells (Fukudome et al., 1992b). The
present study shows that this alteration could be the
result, at least partly, of the presence of HTLV-1 envelope
glycoproteins in these cells. The protein domains in-
volved in these reciprocal interactions have yet to be
identified. Finally, HTLV-1 also modulates the expression
of integrin-type adhesion molecules and their ligands
(Fukudome et al., 1992a; Lal et al., 1992; Imai et al.,
1993a; Owen et al., 1997; Tanaka et al., 1995; Uchiyama et
al., 1996). These phenomena could be important for the
fine modulation of HTLV-1 transmission because HTLV-1,
more than any other retrovirus, is dependent on cellular
contacts for its transmission.
MATERIALS AND METHODS
Cell lines
C91/PL, MT2, CEM-NDK (a gift from U. Hazan, Institut
Cochin de Ge´ne´tique Mole´culaire, Paris, France), and
Jurkat are T-cell lines: C91/PL and MT2 are chronically
infected with HTLV-1 (Popovic et al., 1983) and CEM-
NDK, by HIV-1 (Ellrodt et al., 1984). They were grown in
RPMI 1640 medium supplemented with 10% fetal calfserum (FCS). COS-1 cells were obtained from the Amer-
ican Type Culture Collection (Rockville, MD). The B5 cells
used in the infectivity assay were a gift from Dr. Waters
(Frederick Cancer Research and Development Facility,
Frederick, MD). CosLTRLacZ, which are COS-1 cells sta-
bly expressing the bacterial b-galactosidase gene under
the control of the HIV-1 long terminal repeat (Dragic et
al., 1992); HeLa-Tat cells, which are HeLa cells stably
transfected with a tat gene expressor (Dragic et al.,
1992); and p4.2 cells, which are HeLa cells stably trans-
fected with the human CD4 gene and the HIV-LTR-LacZ
were all obtained from M. Alizon (INSERM U332, ICGM,
Paris, France), and grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% FCS. The 293-TSA cells
used for the incorporation experiments were obtained
from J. Neyton (Ecole Normale Supe´rieure, Paris). All
cells were cultured at 37°C in a 5% CO2 atmosphere.
ntibodies
HTLV-1 envelope glycoproteins were detected with
ooled sera from HTLV-1-infected individuals, or the 4D4
onoclonal antibody obtained from C. Desgranges (IN-
ERM U271, Lyon, France). 4D4 (IgG1) is directed to the
-terminal part of the HTLV-1 SU protein (Grange et al.,
998). HIV-1 envelope glycoproteins were detected with
era from HIV-1-infected individuals. CD82 proteins were
etected using the gC11 MAb (IgG1) described in Lebel-
Binay et al. (1994). The ICAM-1 molecules were revealed
ith an anti-CD54 MAb (Immunotech, Marseille, France).
lasmids
The HTLV-1 wild-type envelope expression vector
sed in this study was the CMV-ENV plasmid described
lsewhere (Delamarre et al., 1997). It contains all the
TLV-1 sequences corresponding to the env, tax, and rex
enes, under the control of the simian cytomegalovirus
CMV) promoter. The CMV-ENV-DPvuII plasmid, which
as obtained by inserting a nonsense codon just after
he sequence coding for signal peptide of the envelope
lycoprotein (Delamarre et al., 1997), is the negative
ontrol for HTLV-1 envelope protein synthesis. The indi-
ator provirus pCS-HTLV-neo has been described else-
here (Delamarre et al., 1997). This plasmid contains the
CS-HTLV-1 provirus (Ciminale et al., 1992) with the env
ene replaced by a neomycin resistance gene under the
ontrol of the simian virus 40 promoter. The CD82 ex-
ressor plasmid CMV-CD82 was constructed by intro-
ucing the cDNA coding for the CD82 protein (Gil et al.,
992) into the CMV-Ex-pA2 plasmid (a gift from E. Cohen,
Montreal, Canada) using a PvuII site. The CMV-Ex-pA2
plasmid contains the CMV promoter, cloning sites, and a
polyadenylation signal, and was used as negative con-
trol in the cotransfection experiments. The HIV-1 enve-
lope/Tat expressor plasmid pMA243 was a gift from M.
Alizon (INSERM U332, ICGM, Paris, France) and has
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462 PIQUE ET AL.been described in Schwartz et al. (1994). The human CD4
expressor plasmid was obtained by F. Triebel (Institut
Gustave Roussy, France).
Transfection procedure
Cells were transfected (Delamarre et al., 1997) using
DEAE Dextran and chloroquine (Sigma, La Verpille`re,
France). Cotransfection experiments generally used 1 mg
of each plasmid; other conditions are specified in the
table legends (Tables 1 and 2).
Syncytium formation assay
Syncytium formation was quantified using a cell-to-cell
fusion assay based on b-galactosidase production (Del-
marre et al., 1997). The fusion of envelope- and recep-
tor-bearing cells causes the Tat-dependent activation of
the LacZ gene placed under the control of the HIV-1 LTR.
TLV-1 envelope-mediated syncytium formation was as-
ayed in cocultures of COSLTRLacZ cells transfected
ith the CMV-Env construct, and indicator HeLa-Tat
ells. HIV-1 envelope-mediated syncytium formation was
ssayed in COS-1 cells transfected with the pMA243
IV-Env/Tat expressor plasmid grown with P4.2 cells for
4 h. The amount of b-galactosidase produced, which is
roportional to the number of syncytia formed, was mea-
ured by a chemiluminescent reporter assay (Galacto-
ight, Tropix, Bedford, MA) in a luminometer (Lumat, LB
501, Berthold, Bundoora, Australia).
nfectivity assay
This is a quantitative evaluation of HTLV-1 cell-to-cell
ransmission in a single round of infection (Delamarre et
l., 1997). Briefly, the pCS-HTLV-neo and the envelope
xpressor were cotransfected, with or without the CD82
xpressor plasmid, into COS-1 cells seeded at 3 3 105
cells per 60-mm dish the day before and incubated for
48 h. The cells were then incubated with 10 mg/ml mit-
mycin C for 3 h at 37°C, washed five times with phos-
hate-buffered saline (PBS), and cultivated with 5 3 105
B5 cells in a 60-mm cell-culture dish for 48 h. The cells
were trypsinized and half of them placed in geneticin-
containing medium (125 mg/ml, G-418 sulfate; Gibco,
rance) for 2 weeks. The resistant colonies were
ounted to calculate the relative infectivity index (Del-
marre et al., 1997).
etection of CD82/envelope protein complexes
Cells were solubilized using 1% CHAPS, a detergent
hat preserves protein–protein interaction, in Tris-buff-
red saline (TBS, 150 mM NaCl, 10 mM Tris–HCl, pH 7.3),
ontaining protease inhibitors (1 mM Pefabloc, 1 mM
protinin, 1 mM iodoacetamide) for 1 h on ice and cen-rifuged at 10,000 g for 15 min at 4°C to pellet the
nsoluble material. Cell lysates were submitted, or not, to
mmunoprecipitation using protein G–Sepharose beads
oated with gC11 or 4D4 Mabs or sera from HTLV-1-
nfected individuals (Pique et al., 1990). Whole-cell ly-
ates or immunoprecipitated proteins were separated by
2% SDS–PAGE under nonreducing conditions to allow
he recognition by the gC11 antibody, and proteins were
ransferred to polyvinylidene difluoride membranes (Du-
ont/New England Nuclear, Boston, MA). The membrane
ere incubated with blocking buffer (TBS, 5% skim milk)
nd then with biotinylated gC11 MAb (1 mg/ml), washed
ive times with PBS–0.05% Tween 20. The washed mem-
ranes were incubated with streptavidin–biotinylated
orseradish peroxidase complex (1 h, 25°C) and immu-
oreactive spots detected with an ECL Western blotting
etection kit (Amersham, Les Ulis, France).
adioimmunoprecipitation of Env and CD82 proteins
n cell lysates and viral particles
Env and CD82 intracellular maturation was assessed
n COS-1-transfected cells or HTLV-1-infected cells la-
eled by incubation for 16 h in 1 ml methionine and
ysteine-free RPMI medium containing 100 mCi Promix
per ml (Amersham) and 10% dialyzed FCS. For pulse-
chase experiments, COS-1 cells transfected with the
CD82 and the envelope protein expressor constructs
were starved for 1 h in methionine- and cysteine-free
medium, and pulse-labeled for 10 min at 37°C with 1.5
mCi/ml of Promix labeling medium containing [35S]cys-
teine and [35S]methionine (Amersham), followed by a
hase (30 min to 6 h) with complete DMEM. Cells were
ysed with NP-40 lysis buffer, and the lysates were im-
unoprecipitated using sera from HTLV-1-infected indi-
iduals or the gC11 MAb.
Incorporation of HTLV-1 envelope proteins into virions
was performed as previously described (Delamarre et
al., 1997). The pCS-HTLV-1-neo plasmid (3 mg) was co-
transfected with the CMV-Env-LTR envelope expressor
(0.5 mg) and the CD82 plasmid (0.5 mg) in 293-TSA cells
sing Fugene 6 reagent (Roche, France). Twenty-four
ours later, the cells were metabolically labeled with 700
mCi/ml (35S)-cysteine-methionine Promix (Amersham).
he cell supernatants were collected, centrifuged for 10
in at 1200 rpm to remove cell debris, and filtered
hrough a 0.45-mm-pore filter. The supernatants were
hen layered onto discontinuous sucrose gradients (3 ml
0% sucrose over 3 ml 60% sucrose) and centrifuged for
h at 4°C at 25,000 rpm in an SW-41 rotor. The virus at
he interface between the two layers was collected in a
olume of 1 ml, to which 200 ml of 53 lysis buffer wasadded. The viral proteins were then immunoprecipitated
using sera from HTLV-1-infected individuals.
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463CD82 INHIBITS HTLV-1 ENVELOPE GLYCOPROTEIN FUNCTIONSCocapping of CD82 and HTLV-1 envelope
glycopoteins
The HTLV-1 chronically infected T-cell lines C91/PL or
MT2, or the HIV-1 chronically infected T cells, CEM-NDK
(3 3 105), were washed in PBS plus 2% FCS (PBS-2%)
nd incubated with saturating concentrations of anti-
TLV-1 or anti-HIV-1 sera (1/100) or gC11 or anti-CD54
Ab (10 mg/ml) in 50 ml PBS-2%, for 30 min at 4°C.
nvelope glycoproteins were capped by twice washing
he cells in PBS-2% and incubating them for 30 min at
°C with a second antibody, fluorescein isothiocyanate-
onjugated rabbit anti-human IgG (diluted 1/50; Caltag,
outh San Francisco, CA). The cells were again twice
ashed in PBS-2% and incubated for 30 min at 37°C, to
nsure complete capping of glycoproteins. Finally, the
ells were washed twice at 4°C in PBS-2% containing
.1% sodium azide, and stained for CD82 with gC11 or
anti-CD54 MAbs, followed by incubation with cy3-conju-
gated goat anti-mouse IgG (1/300 dilution; Jackson Im-
munoresearch Laboratories, West Grove, PA) in cold
PBS-2% plus 0.1% sodium azide, washed twice in the
same medium, and fixed in PBS containing 2% parafor-
maldehyde. Capping of CD82 was induced with the
same protocol, except that the cy3-conjugated goat anti-
mouse IgG was used as the capping MAb and the
fluorescein isothiocyanate-conjugated rabbit anti-human
IgG was used as counterstain. Cells were placed on
coverslips in Moewiol 4-88 supplemented with 1%
DABCO (Sigma Chemical, St. Louis, MO) and stored in
the dark. They were analyzed by confocal laser micros-
copy (BioRad MRC-100 inverted confocal microscope;
BioRad Laboratories, Hercules, CA) equipped with a Dia-
phot 200 digitalizing system. The digitalized pictures
were analyzed using Comos software and processed
with Adobe Photoshop software (Adobe Systems, Moun-
tain View, CA).
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